Polyrizon reports safety study results for PL-14 Allergy Blocker formulation

Polyrizon (PLRZ) announced the preliminary safety study for a formulation of its PL-14 Allergy Blocker. Conducted on fully differentiated human nasal tissue using the MucilAir model, the study demonstrated strong local tolerability. The study was designed to assess local tolerance and tissue response following a 4-hour application of a formulation of PL-14, a mucoadhesive nasal gel spray formulated to act as a physical barrier against airborne allergens. PL-14 Allergy Blocker is intended to remain in the nasal cavity for approximately 4 hours post-application. Key safety indicators, including tissue integrity, cytotoxicity, cilia beating frequency, mucociliary clearance, and inflammatory response were evaluated in comparison to untreated and vehicle control groups. Tissue viability and function remained consistent with baseline and vehicle controls. No signs of inflammatory activation or functional impairment of nasal epithelial activity were observed under the tested conditions. This contributes to the company’s broader verification and validation program ahead of its planned clinical trials and FDA pre-submission meeting. The data serve as a key step in Polyrizon’s regulatory strategy and will support its upcoming FDA pre-submission meeting, paving the way for U.S. and European clinical trials expected to begin in late 2025 or early 2026.